Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Leukemia & MDS Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for RUNX1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | RUNX1 Recombinant / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View RUNX1 Products |
| Gene Delivery | RUNX1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View RUNX1 Products |
| Benchmark Ab | Anti-RUNX1 (Sequence Validated) Recombinant positive control. |
View RUNX1 Products |
| Validator | RUNX1 siRNA Set For knockdown verification. |
View RUNX1 Products |
| Related Target A | CBFB Forms the core binding factor complex with RUNX1. |
View CBFB Products |
| Related Target B | FLT3 Frequently co-mutated in AML, essential for combination therapy. |
View FLT3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Evaluating Protein-Protein Interaction (RUNX1-CBFB) | High-purity soluble proteins (>95%) optimized for SPR and TR-FRET assays. |
| Testing Mutant-Specific Inhibitors | Clinical mutants (e.g., S114L, D171N) available with Sequence Verified accuracy. |
| Lack of Controls | Clinical Benchmark Antibodies included |
| False Positives | Validated siRNA included for specificity checks |
Live RUNX1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for RUNX1 therapeutics is intensifying, with major players shifting focus from traditional chemotherapy to Targeted Protein Degraders (PROTACs) and small molecule PPI inhibitors. As first-generation therapies reach the clinic, the next wave of R&D is targeting mutant-specific vulnerabilities and combination strategies in AML and MDS.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Mol (PPI Inhibitor) | Illumina, Academic Spin-offs | AML, MDS | PPI Assay (Need high-purity RUNX1 and CBFB) |
| PROTAC / Degrader | Arvinas, Kymera (Early Stage) | Leukemia | Degradation Assay (Need specific Abs and ORFs) |
| Gene Therapy | Various Biotech | Familial Platelet Disorder | Expression Validation (Need specific Abs) |